AlphaCentric Life Sciences & Hlthcare C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
AlphaCentric Life Sciences and Healthcare Fund Class C LYFCX
- NAV / 1-Day Return 17.06 / −1.84 %
- Total Assets 46.4M
-
Adj. Expense Ratio
2.410%
- Expense Ratio 2.400%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.66%
- Turnover 107%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 12:55 AM GMT+0
Morningstar’s Analysis LYFCX
Will LYFCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 39.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Gilead Sciences Inc | 5.53 | 3M | Healthcare |
Vertex Pharmaceuticals Inc | 5.32 | 2M | Healthcare |
AstraZeneca PLC | 4.63 | 2M | Healthcare |
First American Treasury Obligs X | 4.25 | 2M | Cash and Equivalents |
Roivant Sciences Ltd Ordinary Shares | 3.67 | 2M | Healthcare |
argenx SE ADR | 3.59 | 2M | Healthcare |
Neurocrine Biosciences Inc | 3.51 | 2M | Healthcare |
Incyte Corp | 3.51 | 2M | Healthcare |
Axsome Therapeutics Inc | 3.42 | 2M | Healthcare |
Apogee Therapeutics Inc | 3.28 | 2M | Healthcare |
United States